Month: March 2022

HORSHAM, Pa., March 03, 2022 (GLOBE NEWSWIRE) — STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, today announced the Company will participate in the upcoming Oppenheimer 32nd Annual Healthcare Conference. STRATA Skin Sciences’ management is scheduled to present on Tuesday, March 15th at 2:00 pm Eastern Time. Management will also participate in 1×1 meetings throughout out the day. Interested parties may access a live and archived webcast of the presentation on the investor section of the Company’s website at www.strataskinsciences.com. About STRATA Skin Sciences, Inc.STRATA Skin Sciences is a medical technology company in dermatology dedicated to developing, commercializing and marketing...

MINNEAPOLIS, MN, March 03, 2022 (GLOBE NEWSWIRE) — via NewMediaWire – Mitesco, Inc. (OTCQB: MITI), a leading operator of wellness clinics that combine a nurse practitioner model with personalized, whole-person primary care, will host a shareholder update conference call Tuesday, March 8, 2022, at 4:15 p.m. Eastern Time. The call, which will feature a presentation by CEO Larry Diamond of the company’s newly updated investor PowerPoint, will include a discussion of Mitesco’s significant progress on its expansion plans, plans to uplist the company’s common stock to Nasdaq, growth in the activity level of its existing clinics, and other developments. The presentation will be followed by a question-and-answer session, which can be accessed via the webcast link or dial-in numbers below. To view the PowerPoint and presentation and participate...

BRIDGEWATER, N.J., March 03, 2022 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced that David Domzalski, Chief Executive Officer, will participate in a virtual fireside chat at the 42nd Annual Cowen Healthcare Conference on March 8, 2022. Management will also be available for 1-on-1 meetings with investors. Virtual Presentation DetailsDate:   Tuesday, March 8thTime:   12:50 p.m. ETFormat:   Virtual Fireside ChatWebcast Link:   https://wsw.com/webcast/cowen108/vyne/2045898The replay of the webcast will be available on the VYNE website for 90 days following the conference. About VYNE Therapeutics Inc. VYNE’s mission is to...

ZEELAND, Mich., March 03, 2022 (GLOBE NEWSWIRE) — Gentex Corporation (NASDAQ: GNTX), the Zeeland, Michigan-based supplier of digital vision, connected car, dimmable glass, and fire protection technologies, today announced that its Board of Directors recently declared a quarterly cash dividend of $0.12 (12 cents) per share that will be payable April 20, 2022, to shareholders of record of the common stock at the close of business on April 8, 2022. About the CompanyFounded in 1974, Gentex Corporation (The NASDAQ Global Select Market: GNTX) is a supplier of automatic-dimming rearview mirrors and electronics to the automotive industry, dimmable aircraft windows for aviation markets, and fire protection products to the fire protection market. Visit the Company’s websites at www.gentex.com, fulldisplaymirror.com, and gentextech.com. Contact...

Community bank chooses nCino’s robust, single platform to best serve its community WILMINGTON, N.C., March 03, 2022 (GLOBE NEWSWIRE) — nCino, Inc. (NASDAQ: NCNO), a pioneer in cloud banking and digital transformation solutions for the global financial services industry, today announced that $4 billion-asset sized SmartBank, a subsidiary of SmartFinancial, Inc. (“SmartFinancial” or the “Company”; NASDAQ: SMBK) is moving to the nCino Bank Operating System®. SmartBank will utilize nCino’s Commercial Banking Solution, which will provide the institution a robust, digitized, end-to-end experience for all its clients. “We know that investing in technology is crucial in the current digital landscape, but it’s even more critical to have the knowledge and understanding on where to best allocate that investment. We’ve been...

Phase 3 ATTACK registrational trial for sulbactam-durlobactam (SUL-DUR) achieved all primary and secondary endpoints, NDA submission planned for mid-2022 Zoliflodacin Phase 3 trial progressing; enrollment completion now anticipated in 2023 Entasis’ pathogen-directed platform and latest candidate ETX0462 highlighted by seminal publication in the prestigious scientific journal Nature Receipt of acquisition proposal from existing majority shareholder Innoviva, Inc.WALTHAM, Mass., March 03, 2022 (GLOBE NEWSWIRE) — Entasis Therapeutics Holdings Inc. (Nasdaq: ETTX), a late-stage clinical biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced full year 2021 financial results and provided a business update. “The incredible effort and commitment of our employees and partners...

Learn more about Mydecine’s clinical trials and drug development strategy by scheduling a meeting with management DENVER, March 03, 2022 (GLOBE NEWSWIRE) — Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), a biotechnology company aiming to transform the treatment of mental health and addiction disorders, today announced the company will be attending three conferences for investors in March – the 34th Annual Roth Conference, the Oppenheimer & Co. Annual Healthcare Conference and Maxim Group’s Virtual Growth Conference. Members of Mydecine’s management team will be available for one-on-one or small group meetings with participants. To schedule a meeting, please email contact@mydecineinc.com. The 34th Annual ROTH Conference, hosted by ROTH Capital Partners, will be held in person...

AUSTIN, Texas, March 03, 2022 (GLOBE NEWSWIRE) — Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a U.S. clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, today announced it will sponsor and present an industry satellite symposium at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Therapeutics Conference, being held in-person March 10-12, 2022 at the Hyatt Regency, New Orleans, Louisiana. Details of the symposium are as follows:Title Radiolabeled NanoLiposomes: A Novel Targeted Treatment for Rare and Central Nervous System CancersDate March 12, 2022 at 7:15 – 8:00 a.m. CTLocation Hyatt Regency, Elite B Main Meeting Room, New Orleans, LouisianaPresenter Norman LaFrance, MD, ME, FACP, FACNP, FACNM; Chief Medical Officer...